LeadIQ logo
Learn more at LeadIQ.com

Insights

Recent Collaborations Alnylam recently entered a collaboration agreement with PeptiDream to develop peptide-siRNA conjugates for targeted delivery of RNAi therapeutics. This partnership opens up opportunities for joint sales efforts and expanded market reach.

Financial Recognition Alnylam attracted investments from Moloney Securities Asset Management, showcasing confidence in the company's financial health and growth potential. Leveraging this backing can lead to increased funding for sales expansion and new market penetration strategies.

Product Launch Success Alnylam's successful drug launches of Givlaari and Onpattro indicate a strong track record of bringing innovative therapies to market. Highlighting these achievements can attract new customers and drive sales growth.

Industry Recognition Being recognized as a Humankind 100 company for three consecutive years and consistently ranking as a top employer reflects Alnylam's positive reputation and commitment to excellence. Utilizing these accolades in sales pitches can enhance credibility and attract potential clients.

Market Expansion Opportunities Alnylam's presence in the biotechnology research industry and continuous development of new therapies position the company well for expansion into new markets and partnerships. Identifying and targeting emerging market segments can lead to increased sales opportunities and business growth.

Similar companies to Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Tech Stack

Alnylam Pharmaceuticals uses 8 technology products and services including SiteCatalyst, WordPress, SurveyMonkey, and more. Explore Alnylam Pharmaceuticals's tech stack below.

  • SiteCatalyst
    Analytics
  • WordPress
    Content Management System
  • SurveyMonkey
    Customer Feedback Management
  • Underscore.js
    Javascript Libraries
  • Microsoft Azure
    Platform As A Service
  • C++
    Programming Languages
  • Buildout
    Real Estate Marketing
  • Apache
    Web Servers

Media & News

Alnylam Pharmaceuticals's Email Address Formats

Alnylam Pharmaceuticals uses at least 1 format(s):
Alnylam Pharmaceuticals Email FormatsExamplePercentage
FLast@alnylam.comJDoe@alnylam.com
93%
First.Last@alnylam.comJohn.Doe@alnylam.com
5%
FiLast@alnylam.comJoDoe@alnylam.com
1%
FirstLast@alnylam.comJohnDoe@alnylam.com
1%

Frequently Asked Questions

Where is Alnylam Pharmaceuticals's headquarters located?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's main headquarters is located at 675 W Kendall St Cambridge, Massachusetts 02142 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Alnylam Pharmaceuticals's phone number?

Minus sign iconPlus sign icon
You can contact Alnylam Pharmaceuticals's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Alnylam Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals is a publicly traded company; the company's stock symbol is ALNY.

What is Alnylam Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's official website is alnylam.com and has social profiles on LinkedIn.

How much revenue does Alnylam Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of November 2024, Alnylam Pharmaceuticals's annual revenue reached $1.8B.

What is Alnylam Pharmaceuticals's SIC code NAICS code?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 325412 - Pharmaceutical Preparation Manufacturing.

How many employees does Alnylam Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of November 2024, Alnylam Pharmaceuticals has approximately 2.4K employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: Y. G.Chief Executive Officer: D. C.Chief Executive Officer & Director: J. M.. Explore Alnylam Pharmaceuticals's employee directory with LeadIQ.

What industry does Alnylam Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Alnylam Pharmaceuticals use?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's tech stack includes SiteCatalystWordPressSurveyMonkeyUnderscore.jsMicrosoft AzureC++BuildoutApache.

What is Alnylam Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's email format typically follows the pattern of . Find more Alnylam Pharmaceuticals email formats with LeadIQ.

How much funding has Alnylam Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of November 2024, Alnylam Pharmaceuticals has raised $900M in funding. The last funding round occurred on Sep 13, 2022 for $900M.

When was Alnylam Pharmaceuticals founded?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals was founded in 2002.
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Biotechnology ResearchMassachusetts, United States1001-5000 Employees

ALNYLAM IS LEADING THE RNAi REVOLUTION™

Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.

Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.

We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024).

We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.

See our social media community guidelines: https://bit.ly/2FcRhJy.

Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Section iconCompany Overview

Headquarters
675 W Kendall St Cambridge, Massachusetts 02142 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ALNY
NAICS Code
325412 - Pharmaceutical Preparation Manufacturing
Founded
2002
Employees
1001-5000

Section iconFunding & Financials

  • $900M

    Alnylam Pharmaceuticals has raised a total of $900M of funding over 8 rounds. Their latest funding round was raised on Sep 13, 2022 in the amount of $900M.

  • $1B

    Alnylam Pharmaceuticals's revenue is in the range of $1B

Section iconFunding & Financials

  • $900M

    Alnylam Pharmaceuticals has raised a total of $900M of funding over 8 rounds. Their latest funding round was raised on Sep 13, 2022 in the amount of $900M.

  • $1B

    Alnylam Pharmaceuticals's revenue is in the range of $1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.